Pharmacotherapy in bronchiolitis at discharge from emergency departments within the Pediatric Emergency Research Networks: a retrospective analysis

Pediatric Emergency Research Networks

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Clinical guidelines advise against pharmacotherapy in bronchiolitis. However, little is known about global variation in prescribing practices for bronchiolitis at discharge from emergency departments. We aimed to evaluate global variation in prescribing practice (ie, inhaled salbutamol, or oral or inhaled corticosteroids) for infants with bronchiolitis at discharge from emergency departments. Methods: We did a planned secondary analysis of a multinational, retrospective cohort study of the Pediatric Emergency Research Networks. Previously healthy infants (aged <12 months) who were discharged with bronchiolitis between Jan 1 and Dec 31, 2013 from 38 emergency departments in Australia and New Zealand, Canada, Spain and Portugal, the UK and Ireland, and the USA were included. The primary outcome was pharmacotherapy prescription at discharge from the emergency department. Secondary outcomes were revisits to the emergency department or hospitalisations for bronchiolitis within 21 days of discharge. Findings: Of 1566 infants discharged from the emergency department, 317 (20%) were prescribed pharmacotherapy. Corticosteroid prescriptions were infrequent, ranging from 0% (0 of 68 infants) in Spain and Portugal to 6% (25 of 452) in the USA. Salbutamol prescriptions ranged from 5% (22 of 432) in the UK and Ireland to 32% (146 of 452) in the USA. Compared with the UK and Ireland, the odds of prescription of pharmacotherapy were increased in Spain and Portugal (odds ratio [OR] 9·22, 95% CI 1·70–49·96), the USA (8·20, 2·79–24·11), Canada (5·17, 1·61–16·67), and Australia and New Zealand (1·21, 0·36–4·10). After adjustment for clustering by site, pharmacotherapy at discharge was associated with older age (per 1 month increase; OR 1·23, 95% CI 1·16–1·30), oxygen saturation (per 1% decrease from 100%; 1·09, 1·01–1·18), chest retractions (1·88, 1·26–2·79), network (p=0·00050), and site (p<0·00090). 303 (19%) of 1566 infants returned to the emergency department and 129 (43%) of 303 were hospitalised. Discharge pharmacotherapy was not associated with revisits (p=0·55) or subsequent hospitalisations (p=0·50). Interpretation: Use of ineffective medications in infants with bronchiolitis at discharge from emergency departments is common, with large differences in prescribing practices between countries and emergency departments. Enhanced knowledge translation and deprescribing efforts are needed to optimise and unify the management of bronchiolitis. Funding: None.

Original languageEnglish (US)
Pages (from-to)539-547
Number of pages9
JournalThe Lancet Child and Adolescent Health
Volume3
Issue number8
DOIs
StatePublished - Aug 1 2019

Fingerprint

Bronchiolitis
Hospital Emergency Service
Emergencies
Pediatrics
Drug Therapy
Research
Prescriptions
Portugal
Ireland
Spain
Albuterol
New Zealand
Canada
Adrenal Cortex Hormones
Hospitalization
Odds Ratio
Translational Medical Research
Cluster Analysis
Cohort Studies
Thorax

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Developmental and Educational Psychology

Cite this

@article{c5319cb67a83494eb8f42258887a323b,
title = "Pharmacotherapy in bronchiolitis at discharge from emergency departments within the Pediatric Emergency Research Networks: a retrospective analysis",
abstract = "Background: Clinical guidelines advise against pharmacotherapy in bronchiolitis. However, little is known about global variation in prescribing practices for bronchiolitis at discharge from emergency departments. We aimed to evaluate global variation in prescribing practice (ie, inhaled salbutamol, or oral or inhaled corticosteroids) for infants with bronchiolitis at discharge from emergency departments. Methods: We did a planned secondary analysis of a multinational, retrospective cohort study of the Pediatric Emergency Research Networks. Previously healthy infants (aged <12 months) who were discharged with bronchiolitis between Jan 1 and Dec 31, 2013 from 38 emergency departments in Australia and New Zealand, Canada, Spain and Portugal, the UK and Ireland, and the USA were included. The primary outcome was pharmacotherapy prescription at discharge from the emergency department. Secondary outcomes were revisits to the emergency department or hospitalisations for bronchiolitis within 21 days of discharge. Findings: Of 1566 infants discharged from the emergency department, 317 (20{\%}) were prescribed pharmacotherapy. Corticosteroid prescriptions were infrequent, ranging from 0{\%} (0 of 68 infants) in Spain and Portugal to 6{\%} (25 of 452) in the USA. Salbutamol prescriptions ranged from 5{\%} (22 of 432) in the UK and Ireland to 32{\%} (146 of 452) in the USA. Compared with the UK and Ireland, the odds of prescription of pharmacotherapy were increased in Spain and Portugal (odds ratio [OR] 9·22, 95{\%} CI 1·70–49·96), the USA (8·20, 2·79–24·11), Canada (5·17, 1·61–16·67), and Australia and New Zealand (1·21, 0·36–4·10). After adjustment for clustering by site, pharmacotherapy at discharge was associated with older age (per 1 month increase; OR 1·23, 95{\%} CI 1·16–1·30), oxygen saturation (per 1{\%} decrease from 100{\%}; 1·09, 1·01–1·18), chest retractions (1·88, 1·26–2·79), network (p=0·00050), and site (p<0·00090). 303 (19{\%}) of 1566 infants returned to the emergency department and 129 (43{\%}) of 303 were hospitalised. Discharge pharmacotherapy was not associated with revisits (p=0·55) or subsequent hospitalisations (p=0·50). Interpretation: Use of ineffective medications in infants with bronchiolitis at discharge from emergency departments is common, with large differences in prescribing practices between countries and emergency departments. Enhanced knowledge translation and deprescribing efforts are needed to optimise and unify the management of bronchiolitis. Funding: None.",
author = "{Pediatric Emergency Research Networks} and Alisha Jamal and Yaron Finkelstein and Nathan Kuppermann and Freedman, {Stephen B.} and Florin, {Todd Adam} and Babl, {Franz E.} and Dalziel, {Stuart R.} and Roger Zemek and Plint, {Amy C.} and Steele, {Dale W.} and David Schnadower and Johnson, {David W.} and Derek Stephens and Anupam Kharbanda and Damian Roland and Lyttle, {Mark D.} and Macias, {Charles G.} and Fernandes, {Ricardo M.} and Javier Benito and Suzanne Schuh",
year = "2019",
month = "8",
day = "1",
doi = "10.1016/S2352-4642(19)30193-2",
language = "English (US)",
volume = "3",
pages = "539--547",
journal = "The Lancet Child and Adolescent Health",
issn = "2352-4642",
publisher = "Elsevier BV",
number = "8",

}

Pharmacotherapy in bronchiolitis at discharge from emergency departments within the Pediatric Emergency Research Networks : a retrospective analysis. / Pediatric Emergency Research Networks.

In: The Lancet Child and Adolescent Health, Vol. 3, No. 8, 01.08.2019, p. 539-547.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pharmacotherapy in bronchiolitis at discharge from emergency departments within the Pediatric Emergency Research Networks

T2 - a retrospective analysis

AU - Pediatric Emergency Research Networks

AU - Jamal, Alisha

AU - Finkelstein, Yaron

AU - Kuppermann, Nathan

AU - Freedman, Stephen B.

AU - Florin, Todd Adam

AU - Babl, Franz E.

AU - Dalziel, Stuart R.

AU - Zemek, Roger

AU - Plint, Amy C.

AU - Steele, Dale W.

AU - Schnadower, David

AU - Johnson, David W.

AU - Stephens, Derek

AU - Kharbanda, Anupam

AU - Roland, Damian

AU - Lyttle, Mark D.

AU - Macias, Charles G.

AU - Fernandes, Ricardo M.

AU - Benito, Javier

AU - Schuh, Suzanne

PY - 2019/8/1

Y1 - 2019/8/1

N2 - Background: Clinical guidelines advise against pharmacotherapy in bronchiolitis. However, little is known about global variation in prescribing practices for bronchiolitis at discharge from emergency departments. We aimed to evaluate global variation in prescribing practice (ie, inhaled salbutamol, or oral or inhaled corticosteroids) for infants with bronchiolitis at discharge from emergency departments. Methods: We did a planned secondary analysis of a multinational, retrospective cohort study of the Pediatric Emergency Research Networks. Previously healthy infants (aged <12 months) who were discharged with bronchiolitis between Jan 1 and Dec 31, 2013 from 38 emergency departments in Australia and New Zealand, Canada, Spain and Portugal, the UK and Ireland, and the USA were included. The primary outcome was pharmacotherapy prescription at discharge from the emergency department. Secondary outcomes were revisits to the emergency department or hospitalisations for bronchiolitis within 21 days of discharge. Findings: Of 1566 infants discharged from the emergency department, 317 (20%) were prescribed pharmacotherapy. Corticosteroid prescriptions were infrequent, ranging from 0% (0 of 68 infants) in Spain and Portugal to 6% (25 of 452) in the USA. Salbutamol prescriptions ranged from 5% (22 of 432) in the UK and Ireland to 32% (146 of 452) in the USA. Compared with the UK and Ireland, the odds of prescription of pharmacotherapy were increased in Spain and Portugal (odds ratio [OR] 9·22, 95% CI 1·70–49·96), the USA (8·20, 2·79–24·11), Canada (5·17, 1·61–16·67), and Australia and New Zealand (1·21, 0·36–4·10). After adjustment for clustering by site, pharmacotherapy at discharge was associated with older age (per 1 month increase; OR 1·23, 95% CI 1·16–1·30), oxygen saturation (per 1% decrease from 100%; 1·09, 1·01–1·18), chest retractions (1·88, 1·26–2·79), network (p=0·00050), and site (p<0·00090). 303 (19%) of 1566 infants returned to the emergency department and 129 (43%) of 303 were hospitalised. Discharge pharmacotherapy was not associated with revisits (p=0·55) or subsequent hospitalisations (p=0·50). Interpretation: Use of ineffective medications in infants with bronchiolitis at discharge from emergency departments is common, with large differences in prescribing practices between countries and emergency departments. Enhanced knowledge translation and deprescribing efforts are needed to optimise and unify the management of bronchiolitis. Funding: None.

AB - Background: Clinical guidelines advise against pharmacotherapy in bronchiolitis. However, little is known about global variation in prescribing practices for bronchiolitis at discharge from emergency departments. We aimed to evaluate global variation in prescribing practice (ie, inhaled salbutamol, or oral or inhaled corticosteroids) for infants with bronchiolitis at discharge from emergency departments. Methods: We did a planned secondary analysis of a multinational, retrospective cohort study of the Pediatric Emergency Research Networks. Previously healthy infants (aged <12 months) who were discharged with bronchiolitis between Jan 1 and Dec 31, 2013 from 38 emergency departments in Australia and New Zealand, Canada, Spain and Portugal, the UK and Ireland, and the USA were included. The primary outcome was pharmacotherapy prescription at discharge from the emergency department. Secondary outcomes were revisits to the emergency department or hospitalisations for bronchiolitis within 21 days of discharge. Findings: Of 1566 infants discharged from the emergency department, 317 (20%) were prescribed pharmacotherapy. Corticosteroid prescriptions were infrequent, ranging from 0% (0 of 68 infants) in Spain and Portugal to 6% (25 of 452) in the USA. Salbutamol prescriptions ranged from 5% (22 of 432) in the UK and Ireland to 32% (146 of 452) in the USA. Compared with the UK and Ireland, the odds of prescription of pharmacotherapy were increased in Spain and Portugal (odds ratio [OR] 9·22, 95% CI 1·70–49·96), the USA (8·20, 2·79–24·11), Canada (5·17, 1·61–16·67), and Australia and New Zealand (1·21, 0·36–4·10). After adjustment for clustering by site, pharmacotherapy at discharge was associated with older age (per 1 month increase; OR 1·23, 95% CI 1·16–1·30), oxygen saturation (per 1% decrease from 100%; 1·09, 1·01–1·18), chest retractions (1·88, 1·26–2·79), network (p=0·00050), and site (p<0·00090). 303 (19%) of 1566 infants returned to the emergency department and 129 (43%) of 303 were hospitalised. Discharge pharmacotherapy was not associated with revisits (p=0·55) or subsequent hospitalisations (p=0·50). Interpretation: Use of ineffective medications in infants with bronchiolitis at discharge from emergency departments is common, with large differences in prescribing practices between countries and emergency departments. Enhanced knowledge translation and deprescribing efforts are needed to optimise and unify the management of bronchiolitis. Funding: None.

UR - http://www.scopus.com/inward/record.url?scp=85068527603&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068527603&partnerID=8YFLogxK

U2 - 10.1016/S2352-4642(19)30193-2

DO - 10.1016/S2352-4642(19)30193-2

M3 - Article

C2 - 31182422

AN - SCOPUS:85068527603

VL - 3

SP - 539

EP - 547

JO - The Lancet Child and Adolescent Health

JF - The Lancet Child and Adolescent Health

SN - 2352-4642

IS - 8

ER -